Bayer's shares have been on a rollercoaster ride due to the legal proceedings related to
Roundup case. The shares took a sharp turn upwards when the German pharma giant emerged victorious in the US Roundup legal battle, leading to an
11% soar in stock value. The victory also spurred an upgrade in the stock by Bank of America given the positive progress in litigation concerns. However, investor reactions varied when the
quarterly results were mixed with profits falling less than expected but with continued weakness. The company also is planning a
restructuring phase, including managerial cuts in Asia and Europe, holding off on breakup plans despite investor pressures. On the front of new ventures, Bayer is teaming up with NextRNA to develop therapeutics for oncology. Bayer's stock plunged after a trial of a potential blockbuster drug was halted. Some investors are wary due to the company’s reliance on debt, seen as extensive. Nevertheless, the company continues to press forward in other areas, such as developing drugs for chronic kidney disease.
BAYER Stocks News Analytics from Mon, 20 Nov 2023 08:00:00 GMT to Fri, 04 Oct 2024 05:00:52 GMT -
Rating 1
- Innovation -5
